Cell & Gene Therapy Company Accelerate Proprietary MSC Therapy For Covid In Less Than 6 Months

A biotechnology company developing cell and gene therapies was eager to develop an effective treatment targeting COVID-induced ARDS. Knowing that mesenchymal stromal cells (MSCs) may have potential benefits in modulating cytokine storm in ARDS, the team wanted to leverage their platform to develop a potent MSC therapy quickly. In order to respond to the urgency of this need, Company B needs to find a partner who could provide a translation ready MSC platform to accelerate this new clinical program.

RoosterBio’s off-the-shelf hMSC manufacturing ecosystem accelerated their product development by providing RUO hMSC products for early stage, economic evaluation of the system before the program matured into the GMP hMSC product portfolio.